Growth factor allogeneic PBSC mobilization indication requires separate data from autologous setting.
GROWTH FACTOR ALLOGENEIC PBSC MOBILIZATION INDICATION REQUIRES SEPARATE DATA and should not be extrapolated from data on use of hematopoietic growth factors in peripheral blood stem cell mobilization for autologous transplantion, FDA's Biological Response Modifiers Advisory Committee agreed Nov. 13. Although allogeneic PBSC transplants are performed in many fewer patients than autologous transplants, the committee concurred with FDA Division of Clinical Trial Design & Analysis Director Karen Weiss that "in terms of the labeling, I think that autologous and allogeneic stem cells are different and data should be generated from each of the settings."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth